UK markets closed
NIKKEI 225
29,106.01 +505.60 (+1.77%) HANG SENG
26,038.27 -93.76 (-0.36%) CRUDE OIL
84.57 +0.81 (+0.97%) GOLD FUTURES
1,794.40 -12.40 (-0.69%) DOW
35,832.10 +90.95 (+0.25%) BTC-GBP
45,284.75 -783.89 (-1.70%)
Biogen Inc. (BIIB)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
273.25+3.31 (+1.23%)
As of 3:02PM EDT. Market open.
| Previous close | 269.94 |
| Open | 269.88 |
| Bid | 272.24 x 800 |
| Ask | 272.47 x 1000 |
| Day's range | 267.02 - 273.55 |
| 52-week range | 223.25 - 468.55 |
| Volume | 1,025,825 |
| Avg. volume | 983,798 |
| Market cap | 40.139B |
| Beta (5Y monthly) | 0.47 |
| PE ratio (TTM) | 21.85 |
| EPS (TTM) | 12.50 |
| Earnings date | 20 Oct 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 364.93 |
- Motley Fool
3 Big Problems With Biogen's Q3 Results
Biogen (NASDAQ: BIIB) announced its third-quarter results on Wednesday. It's certainly true that Biogen did top analysts' estimates on both the top and bottom lines. Instead, there were three big problems with Biogen's Q3 results.
- Motley Fool
Why Ionis Pharmaceuticals Stock Is Down 13% This Week
Shares of Ionis Pharmaceuticals (NASDAQ: IONS), a biotechnology company, have fallen around 13.6% since their closing price on Friday, Oct. 15, 2021. Investors were disappointed by phase 3 clinical trial results for tofersen, an experimental treatment for amyotrophic lateral sclerosis. Treatment with tofersen was supposed to help reduce physical symptoms of ALS, a progressive neurodegenerative disorder that affects around 20,000 new U.S. patients annually.
© 2021 Verizon Media. All rights reserved.
